Irina Rivkind Koffler
Stock Analyst at Mizuho
(0.46)
# 3,985
Out of 4,876 analysts
31
Total ratings
25%
Success rate
-16.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Irina Rivkind Koffler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Assumes: Buy | $30 | $9.14 | +228.23% | 4 | Sep 5, 2019 | |
| DERM Journey Medical | Upgrades: Buy | $17 → $14 | $7.14 | +96.08% | 4 | Jun 6, 2019 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $146 → $148 | $106.90 | +38.45% | 6 | May 8, 2019 | |
| PCRX Pacira BioSciences | Upgrades: Neutral | $29 → $38 | $23.48 | +61.84% | 4 | May 6, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $61 → $63 | $31.16 | +102.18% | 2 | Dec 17, 2018 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $28 → $29 | $16.76 | +73.03% | 7 | Sep 17, 2018 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Buy | n/a | $0.73 | - | 4 | May 2, 2018 |
Evolus
Sep 5, 2019
Assumes: Buy
Price Target: $30
Current: $9.14
Upside: +228.23%
Journey Medical
Jun 6, 2019
Upgrades: Buy
Price Target: $17 → $14
Current: $7.14
Upside: +96.08%
Jazz Pharmaceuticals
May 8, 2019
Maintains: Neutral
Price Target: $146 → $148
Current: $106.90
Upside: +38.45%
Pacira BioSciences
May 6, 2019
Upgrades: Neutral
Price Target: $29 → $38
Current: $23.48
Upside: +61.84%
Supernus Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $61 → $63
Current: $31.16
Upside: +102.18%
Teva Pharmaceutical Industries
Sep 17, 2018
Maintains: Buy
Price Target: $28 → $29
Current: $16.76
Upside: +73.03%
Ironwood Pharmaceuticals
May 2, 2018
Upgrades: Buy
Price Target: n/a
Current: $0.73
Upside: -